Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jones Lang LaSalle Inc (JLL) vs Novartis AG (NVS) Price & Performance

Jones Lang LaSalle IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Jones Lang LaSalle Inc vs Novartis AG — how do they compare? Jones Lang LaSalle Inc trades at $361.02 (market cap $16.72B), while Novartis AG trades at $152.4 (market cap $295.37B). The key difference: Novartis AG is far larger — about 17.7× Jones Lang LaSalle Inc's market cap, and Novartis AG pays a 3.07% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.

JLLNVS
Market Cap
$16.72B$295.37B
Sector
Real EstateHealth
52-Week High
$373.24$168.62
52-Week Low
$280.16$119.31
Enterprise Value
$19.48B$336.69B
Dividend Yield
3.07%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jones Lang LaSalle Inc

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.

Read more on JLL

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS